We have located links that may give you full text access.
English Abstract
Journal Article
[Mobilization of autologous peripheral blood stem cells by combined chemotherapy and rhG-CSF].
OBJECTIVE: To study the effect of cyclophosphamide (CTX) combination chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF) on autologous peripheral blood stem cells (APBSC) mobilization.
METHODS: CTX(2.5 +/- 1.0) g/m2 on day 1, VP-16,600-800 mg and/or Ara-C 1.0-2.0 g/m2 on day 2 were injected i.v. rhG-CSF 300 micrograms/d was injected s.c. when the white blood cell (WBC) count reached nadir until one day before APBSC harvest. When the WBC count was over 3.0 x 10(9)/L, peripheral blood mononuclear cell (MNC) collection was performed once per day until the number of MNC collected was > 4 x 10(8)/kg. CFU-GM colony formation and CD34+ cell enumeration were performed.
RESULTS: Twenty cases were studied. The lowest level of WBC was (1.2 +/- 0.8) x 10(9)/L on day 8.5 +/- 1.5 following chemotherapy. rhG-CSF was given from day 9.0 +/- 2.0 and continued for 6.0 +/- 1.0 days. APBSC harvest began on day 12.0 +/- 2.0 and continued for 4.0 +/- 1.0 days. A total of (6.14 +/- 2.34) x 10(8)/kg MNC and (23.25 +/- 30.56) x 10(6)/kg CD34+ cells was procured. Peak level of CD34+ cells was observed 14.6 +/- 1.8 days after chemotherapy and 4.9 +/- 1.6 days after rhG-CSF administration. CFU-GM was (21.68 +/- 15.39) x 10(4)/kg when rhG-CSF was given for 4.9 +/- 1.6 days. No severe toxic reaction was observed. Hematopoietic reconstitution was very well in all patients received APBSC transplantation.
CONCLUSION: CTX combination chemotherapy followed by rhG-CSF was safe and feasible for APBSC mobilization.
METHODS: CTX(2.5 +/- 1.0) g/m2 on day 1, VP-16,600-800 mg and/or Ara-C 1.0-2.0 g/m2 on day 2 were injected i.v. rhG-CSF 300 micrograms/d was injected s.c. when the white blood cell (WBC) count reached nadir until one day before APBSC harvest. When the WBC count was over 3.0 x 10(9)/L, peripheral blood mononuclear cell (MNC) collection was performed once per day until the number of MNC collected was > 4 x 10(8)/kg. CFU-GM colony formation and CD34+ cell enumeration were performed.
RESULTS: Twenty cases were studied. The lowest level of WBC was (1.2 +/- 0.8) x 10(9)/L on day 8.5 +/- 1.5 following chemotherapy. rhG-CSF was given from day 9.0 +/- 2.0 and continued for 6.0 +/- 1.0 days. APBSC harvest began on day 12.0 +/- 2.0 and continued for 4.0 +/- 1.0 days. A total of (6.14 +/- 2.34) x 10(8)/kg MNC and (23.25 +/- 30.56) x 10(6)/kg CD34+ cells was procured. Peak level of CD34+ cells was observed 14.6 +/- 1.8 days after chemotherapy and 4.9 +/- 1.6 days after rhG-CSF administration. CFU-GM was (21.68 +/- 15.39) x 10(4)/kg when rhG-CSF was given for 4.9 +/- 1.6 days. No severe toxic reaction was observed. Hematopoietic reconstitution was very well in all patients received APBSC transplantation.
CONCLUSION: CTX combination chemotherapy followed by rhG-CSF was safe and feasible for APBSC mobilization.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app